Merck's Keytruda Regime Approved In Canada For Early Breast Cancer Setting
- Health Canada has approved Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) for adult patients with high-risk early-stage triple-negative breast cancer (TNBC) setting.
- The approval covers Keytruda combined with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.
- Related: EMA's Advisory Group Backs Approval For Merck's Keytruda In Various Cancer Settings.
- The nod is based on Phase 3 KEYNOTE-522 trial results, demonstrating a statistically significant improvement in patients' event-free survival (EFS) and pathological complete response (pCR) rate.
- Keytruda was first approved in Canada in 2015 and currently has cancer indications.
- Price Action: MRK shares are up 0.07% at $86.97 during the premarket session on Monday's last check.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: breast cancer Briefs CanadaBiotech News Health Care General
